Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential

Frontiers in Nutrition, Год журнала: 2025, Номер 12

Опубликована: Фев. 11, 2025

Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder characterized by irregularities in gonadotropin secretion, hyperandrogenism, chronic anovulation, and polycystic ovarian morphology. In addition, it often associated with metabolic dysfunctions, most notably insulin resistance (IR). This affects approximately 6–20% of individuals, primarily emerging during early adolescence, considerably increases the risk conditions such as impaired glucose tolerance, type 2 diabetes, endometrial cancer, cardiovascular diseases, dyslipidemia, postpartum complications. To date, there no standardized protocol for treating PCOS. Existing therapies rely on personalized pharmacotherapy lifestyle modifications. However, these treatments may lead to adverse effects, medications prescribed PCOS are used off-label have not secured approval from U.S. Food Drug Administration specifically this condition. Recently, natural compounds garnered considerable attention due their efficacy hormone modulation minimal toxicity. Substances myo-inositol, resveratrol, berberine, quercetin shown promise mitigating symptoms. Their multi-target properties offer potential achieve outcomes unattainable single-target pharmaceuticals, particularly managing heterogeneous conditions. review aims comprehensively analyze vivo vitro research alongside clinical interventions evaluate influence prevalence therapeutic potential. These investigations lay groundwork developing innovative strategies

Язык: Английский

Impaired glucose tolerance and insulin resistance in a prenatally‐androgenized rat model of polycystic ovary syndrome in later life

Experimental Physiology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 29, 2024

Abstract Polycystic ovary syndrome (PCOS), one of the most common endocrine disorders in reproductive‐aged women, is associated with metabolic disturbances. The present study aimed to examine changes body weight (BW) and glucose insulin tolerance a prenatally‐androgenized (PNA) rat model PCOS compared control increasing age. Pregnant rats experimental group were subcutaneously injected 5 mg free testosterone on 20th day pregnancy, while received solvent. Female offspring both groups, PNA (rat PCOS) control, examined terms BW, at 3, 6, 12 20 months BW birth (6.53 ± 0.89 vs. 5.60 1.18 g; P = 0.038), 15 (25 1.15 22.36 3.98 0.019) 30 (59.37 10.19 vs.49.9 9.39 0.022) days age was significantly increased but no significant differences observed 60 ( 0.155) 75 0.932) or 3 0.239), 6 0.782), 0.755) 0.092) Rat showed impaired (IGT) 0.020) resistance (IR) (3–20 age) control. Increased before puberty, IGT IR our PCOS. This may contribute better understanding underlying mechanisms future studies.

Язык: Английский

Upregulation of PD-L1 contributes to improving the apoptosis of granulosa cells via the PI3K/AKT pathway in PCOS

Journal of Assisted Reproduction and Genetics, Год журнала: 2024, Номер unknown

Опубликована: Дек. 11, 2024

Язык: Английский